The Movement Disorder Society--14th International Congress of Parkinson's Disease and Movement Disorders.
The 14th International Congress of Parkinson's Disease and Movement Disorders, held in Buenos Aires, included topics covering new therapeutic developments in the field of Parkinson's disease and other movement disorders. This conference report highlights selected presentations on drug treatments for movement disorders, including safinamide (Merck Serono SA), PYM-50028 (Phytopharm plc), droxidopa, pardoprunox (Abbott Laboratories); treatment considerations for dystonia; exploiting existing drugs for new indications; and using genetics to assess drug therapy responses.
Grosset
Donald
D
Southern General Hospital, Department of Neurology, Institute of Neurological Sciences, Glasgow, UK. d.grosset@clinmed.gla.ac.uk
Grosset
Andrew
A
D000978:Antiparkinson Agents / Q000627:therapeutic use*; D019274:Botulinum Toxins, Type A / Q000627:therapeutic use; D015507:Drugs, Investigational / Q000627:therapeutic use*; D004421:Dystonia / Q000188:drug therapy; D006801:Humans; D009069:Movement Disorders / Q000188:drug therapy*; D009465:Neuromuscular Agents / Q000627:therapeutic use; D010300:Parkinson Disease / Q000188:drug therapy*
D000978:Antiparkinson Agents; D015507:Drugs, Investigational; D009465:Neuromuscular Agents; D019274:Botulinum Toxins, Type A